About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

22.20 +0.42 (+1.95%)

Streaming Delayed Price Updated: 11:33 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 03, 2024

Via Benzinga

Organon, Howmet Aerospace And More: CNBC's 'Final Trades' ↗

October 03, 2024

On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade.

Via Benzinga

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B ↗

September 18, 2024

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2...

Via Benzinga

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18, 2024

From Roivant Sciences

Via GlobeNewswire

4 Analysts Assess Roivant Sciences: What You Need To Know ↗

September 11, 2024

Via Benzinga

Evaluating Roivant Sciences: Insights From 6 Financial Analysts ↗

June 18, 2024

Via Benzinga

The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts ↗

May 31, 2024

Via Benzinga

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know ↗

April 22, 2024

Via Benzinga

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer ↗

September 10, 2024

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments.

Via Benzinga

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

September 10, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

September 10, 2024

From Roivant Sciences

Via GlobeNewswire

Where Roivant Sciences Stands With Analysts ↗

March 25, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Roivant Sciences ↗

February 14, 2024

Via Benzinga

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? ↗

September 09, 2024

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the...

Via Benzinga

Roivant Provides Update on Graves’ Disease Development Program

September 09, 2024

From Roivant Sciences

Via GlobeNewswire

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗

August 29, 2024

Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.

Via Investor's Business Daily

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

August 08, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

July 25, 2024

From Roivant Sciences

Via GlobeNewswire

ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 ↗

May 30, 2024

ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Via InvestorPlace

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 30, 2024

From Roivant Sciences

Via GlobeNewswire

Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? ↗

May 22, 2024

BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.

Via Benzinga

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

May 16, 2024

From Roivant Sciences

Via GlobeNewswire

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗

May 07, 2024

Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.

Via InvestorPlace

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 ↗

May 01, 2024

Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.

Via InvestorPlace

Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study ↗

April 02, 2024

Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...

Via Benzinga

Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study ↗

April 02, 2024

The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.

Via Investor's Business Daily

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

April 02, 2024

From Roivant Sciences

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

March 29, 2024

Via Benzinga

Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase ↗

March 27, 2024

Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading.

Via Investor's Business Daily

5 Value Stocks In The Healthcare Sector ↗

February 19, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

All News about Roivant Sciences Ltd. - Common Shares

Sections

Services

Contact Information

Follow Us